Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Locally Recurrent LM/LMM Following Surgery

Dermatolog Surg; ePub 2017 Mar 14; Connolly, et al

Publish date:: March 22, 2017

The mean time to local recurrence (LR) of lentigo maligna/lentigo maligna melanoma (LM/LMM) following surgery is at least 57.5 months, underscoring the importance of long-term follow-up, a recent study found. In order to define time to LR in LM/LMM after surgical treatment, and to describe features of observed LR, researchers conducted a retrospective single-center study of consecutive patients presenting with locally recurrent LM/LMM. 649 cases of LM/LMM were reviewed; 29 (21 LM, and 8 LMM) of 41 locally recurrent cases had original histology reports and were included. They found:

For cases presenting as primary LM, LR was also in situ in 14/21 (67%) of cases.
7 of 21 LM recurred as LMM.
Of the 8 primary LMM, 3/8 (37.5%) presented with subsequent LMM and all were slightly deeper on re-excision.

Citation:

Connolly KL, Hibler BP, Lee EH, et al. Locally recurrent lentigo maligna and lentigo maligna melanoma. [Published online ahead of print March 14, 2017]. Dermatolog Surg. doi:10.1097/DSS.0000000000001118.

This Week's Must Reads

Osteoporosis prevalence in PsA similar to general population,

Swedish registry study finds atopic dermatitis significantly associated with autoimmune diseases,

More severe AD correlates with worse sleep health and attention problems in children,

Shortcomings identified in study of acne videos on TikTok,

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Must Reads in Melanoma

Phase 1 study: Beta-blocker may improve melanoma treatment response,

‘Impressive’ results with neoadjuvant T-VEC in advanced melanoma,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Neoadjuvant immunotherapy combo produces high response rate in melanoma,

Vaccine regimen boosts immune response in malignant melanoma,